Hong Kong-listed Metis TechBio has signed a research and development agreement with Eli Lilly (NYSE: LLY) worth up to $1.1 billion. The partnership will focus on improving how medicines reach specific tissues in the body.
Metis is eligible for an upfront payment in the low tens of millions of dollars. Most of the potential deal value is tied to development, regulatory and commercial milestones.
Metis TechBio and Eli Lilly Target More Precise Drug Delivery
Metis TechBio said on October 19 that it will work with Eli Lilly to develop new drug delivery technologies using its AI-driven platform. The goal is to improve the targeting of lipid nanoparticle (LNP) therapies so they can reach intended tissues more effectively.
The Reuters report on the agreement said the collaboration will use Metis’s ionizable lipid discovery and optimization platform to design new LNP structures. These systems can carry therapeutic materials into cells, making delivery precision an important area of drug development.
The companies aim to improve tissue targeting and the distribution of therapies throughout the body. The technology could have applications across several disease areas, although the announcement did not identify specific treatments that will result from the partnership.
Deal Value Depends on Development Milestones and Sales
Metis will receive an upfront payment in the low double-digit millions of US dollars. It may also earn up to about $1.1 billion through development, regulatory and commercial milestone payments. The agreement includes tiered royalties in the single-digit percentage range on annual net sales of products developed through the collaboration.
The potential value is therefore not an immediate cash payment. Much of it depends on whether the research advances through development and regulatory stages and ultimately leads to commercial products.
Eli Lilly will contribute its drug discovery, development and commercialization expertise. The partnership adds another technology-focused research effort to the pharmaceutical company’s work on potential new treatments.
For investors tracking healthcare and pharmaceutical developments, the agreement highlights the growing role of targeted delivery systems in drug research. The financial outcome for Metis will depend on the progress of the programs and whether they produce commercially successful therapies.